NCT06530290View on ClinicalTrials.gov

Evaluating the Effect of Mirtazapine on Anxiety in Parkinson's Disease Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

December 20, 2025

Study Completion Date

June 30, 2026

Conditions
Parkinson DiseaseAnxiety
Interventions
DRUG

Mirtazapine 15 MG

Mirtazapine (15 mg), once a day for 12 weeks

DRUG

Placebo

Placebo, once a day, for 12 weeks

Trial Locations (1)

Unknown

RECRUITING

Shahid Beheshti University of Medical Sciences, Shohada-e-Tajrish Hospital, Tehran

All Listed Sponsors
lead

Leila Dargahi. PharmD PhD

OTHER